A Product Operating Model for Hybrid HL7 v2 and FHIR Interoperability

Hybrid interoperability is a product portfolio, not a temporary phase

Healthcare platforms rarely move from HL7 v2 to FHIR through a clean replacement. Existing interfaces continue to carry clinically and operationally important workflows while new customers, partners, and use cases create demand for APIs and FHIR-based exchange. A product team therefore owns a portfolio of connectivity models, each with different customer expectations, failure modes, implementation effort, and support cost.

Calling the older model “legacy” can hide this product reality. An established interface may be stable, well understood by customer teams, and deeply embedded in a workflow. A newer FHIR capability may offer better discoverability or reuse but still require new authentication, mapping, testing, and support practices. The operating model should compare the value and total operating burden of each path instead of treating standards adoption as the outcome by itself.

Start with a shared problem definition

The first product artifact should explain the user and workflow problem before naming a standard. Identify who needs information, what decision or task it enables, when it must arrive, what happens when it is late or incomplete, and which system is authoritative. This keeps a request for “a FHIR integration” from becoming a solution in search of a problem.

A shared discovery frame also makes different delivery models comparable. The team can assess whether an existing HL7 flow already solves the user problem, whether an API creates a reusable capability, or whether the real constraint sits in identity, data quality, workflow adoption, or partner readiness. Product leadership is the discipline of keeping those alternatives open until the evidence supports a choice.

• Name the affected user, workflow, and decision before the interface.
• Define the minimum useful data and the required timing or reliability.
• Surface authentication, consent, identity, mapping, and support constraints early.
• State what observable change would show that the product problem is solved.

Use one portfolio backlog with explicit classes of work

Separate HL7 and FHIR backlogs often create separate product truths. Customer urgency accumulates in one queue, platform modernization in another, and reliability work in a third. A single portfolio view allows leaders to compare new capability, customer commitments, platform enablement, reliability remediation, and retirement work using the same decision language.

This does not mean every item receives one universal score. Clinical risk, contractual commitments, reusable platform value, implementation friction, and support burden are different kinds of evidence. The important practice is to make them visible. When a customer-specific exception moves ahead of a reusable capability, the decision should explain why and acknowledge the future ownership it creates.

Standardize the operating controls before standardizing every implementation

A hybrid portfolio benefits from common controls even when the technical implementations differ. Discovery expectations, acceptance criteria, dependency ownership, readiness evidence, severity definitions, and post-live review can follow one operating model. This gives product, engineering, implementation, QA, and support teams a consistent way to make decisions across interface engines and APIs.

The standard should describe what must be known and proven, not force every workflow into identical technical behavior. For example, both an HL7 interface and a FHIR API can document the source of truth, mapping assumptions, test evidence, monitoring ownership, escalation path, and rollback or containment plan. The transport and validation details differ, but the decision quality does not need to.

Make exceptions visible product decisions

Healthcare connectivity will always include variation. The goal is not to eliminate exceptions; it is to stop accidental exceptions from becoming permanent platform behavior. An exception should identify the user need, the constraint that prevents the standard path, the owner, the support impact, and the condition that would trigger review or retirement.

This record protects engineering capacity and helps the roadmap. Repeated exceptions may reveal a missing configuration option, an incomplete platform abstraction, or a segment whose needs are genuinely different. Isolated exceptions may be necessary without deserving broader investment. Product teams can only distinguish those cases when the evidence is collected consistently.

• What user or clinical need justifies the deviation?
• Why can the standard path not satisfy it?
• What additional build, test, monitoring, and support ownership follows?
• When will the exception be reviewed, generalized, or retired?

Define success across delivery and operation

Shipping an endpoint or promoting an interface is not sufficient evidence of product success. The operating model should connect delivery evidence to observed use: whether the intended workflow is functioning, whether data-quality exceptions are understood, whether support can diagnose failures, and whether the new path reduces or adds onboarding friction.

The most useful review combines qualitative and operational signals. Implementation teams can describe where discovery still breaks down. Support can identify repeat failure themes. Engineering can show reliability and maintainability concerns. Customers can confirm whether the workflow change is useful. Together, those signals guide remediation, documentation, configuration, and future roadmap choices without relying on a single vanity metric.

Modernization becomes a sequence of product decisions

A credible hybrid strategy does not promise an abrupt standards transition. It establishes where FHIR creates meaningful user or platform value, where HL7 v2 remains the appropriate operating choice, and what capabilities make future migration easier. Shared identity services, mapping governance, monitoring, documentation, and support models may create more leverage than forcing a transport change.

The result is a portfolio that can modernize without abandoning installed-base reality. Product leaders make the tradeoffs explicit, give teams one decision system, and use post-live evidence to adjust the path. That is how interoperability standards become dependable product capabilities rather than parallel technical projects.